NCT00139906

Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia

A Randomized, Double-Blind, Placebo-Controlled, Twice Daily Titration Study of the Safety and Tolerability of Bifeprunox in Subjects With Schizophrenia

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: —
• Sponsor: Solvay Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

This study is to assess the safety and tolerability of a five-day titration schedule (using twice daily dosing for the first three days) to achieve the highest proposed dose of 40 mg daily. The study duration is two months.

Conditions

• Schizophrenia
• Schizoaffective Disorder

Interventions

Type	Name	Description
DRUG	Bifeprunox

Timeline

• Start date: 2005-08-01
• Primary completion: 2006-10-01
• Completion: 2006-10-01
• First posted: 2005-08-31
• Last updated: 2015-01-16

Locations

1 site across 1 country: United States